secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-08-07T12:00:15+00:00
Accession:  0001193125-26-339223
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Q2 2026 net loss widens to $14.3M; FY revenue guidance affirmed at $100.5-111.0M
--------------------------------------------------------------------------------

- Q2 2026 revenue $29.1M, down 2% YoY; GAAP basic EPS $(0.12); net loss $14.3M vs $2.2M loss in Q2 2025.
- Non-GAAP adjusted net loss $12.2M vs $0.6M loss; R&D expense up 129% to $19.1M on F351 and milestone.
- Cullgen acquisition closed May 4, 2026, all-stock ~$300M; Dr. Ying Luo now CEO/President, new CSO/CFO named.
- NDA for F351 (CHB liver fibrosis) accepted by China's CDE in May 2026; full-year revenue guidance reaffirmed.
- Cash, deposits, and investments totaled $103.2M at June 30, 2026, down $12.9M from year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/0001193125-26-339223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000119312526339223/gyre-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-339223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer